Login to Your Account

OSI Buying Cancer Rights To Serono's Novantrone For $55M

By Aaron Lorenzo

Thursday, March 13, 2003
Oncology company OSI Pharmaceuticals Inc. is fronting $55 million to Serono SA for U.S. marketing rights to the cancer indications of a long-approved but oft-shuffled drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription